BiotechTube

Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SC

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis

Conditions

Endometriosis

Trial Timeline

Dec 11, 2006 → Nov 24, 2008

NCT ID
NCT00437658

About Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SC

Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SC is a phase 2 stage product being developed by AbbVie for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00437658. Target conditions include Endometriosis.

What happened to similar drugs?

1 of 19 similar drugs in Endometriosis were approved

Approved (1) Terminated (3) Active (15)
🔄40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
🔄Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
🔄Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
🔄ElagolixAbbViePhase 3
❌elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
🔄ElagolixAbbViePhase 3
🔄elagolixAbbViePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00437658Phase 2Completed

Competing Products

20 competing products in Endometriosis

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
35
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
47
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
29
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
32
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
29
Placebo + ElagolixAbbViePhase 2
35
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
44
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
40
ElagolixAbbViePhase 3
40
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
32
Elagolix + placeboAbbViePhase 2
35
ElagolixAbbViePhase 3
40
elagolixAbbViePhase 3
40
ElagolixAbbViePhase 3
40
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
35
Gefapixant + Placebo + NaproxenMerckPhase 2
35
BGS649 + PlaceboNovartisPhase 2
27
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
35
LetrozoleNovartisPhase 2
35